ImmunityBio Inc
Closed
SectorHealthcare
7.89 2.33
Overview
Share price change
24h
Min
7.71
Max
8.33
Income | -230M -863M |
|---|---|
Sales | 7M 51M |
EPS | -0.08 |
Profit margin | -1,684.596 |
Employees | 684 |
EBITDA | 378M -222M |
Next Earnings | 2 lis 2026 |
|---|
Market Cap | 1.1B 8.6B |
|---|---|
Previous open | 5.56 |
Previous close | 7.89 |
News Sentiment
By Acuity
50%
50%
136 / 339 Ranking in Healthcare
ImmunityBio Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
ImmunityBio Inc Forecast
Sentiment
By Acuity
136 / 339 Ranking in Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About ImmunityBio Inc
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.